Syndrome Antiphospholipid Catastrophic (CAPS / Syndrome Asherson): Tafiotry ny trombose mikrovaskular marobe ao anatin'ny herinandro sy fitsaboana telo miaraka amin'ny Plasmapheresis¶

** Syndrome antiphospholipid catastrophic (CAPS, fantatra amin'ny anarana hoe Asherson's Syndrome taorian'ny Dr. Ronald Asherson, izay nanoritsoritra azy voalohany tamin'ny 1992)** no variana mahafaty indrindra amin'ny Antiphospholipid Syndrome (APS), mamely latsaky ny 1 percent ny marary APS (with nearly 50 percent of cases occurring as the very first clinical presentation in a patient who never knew they had APS). Raha ny APS mahazatra matetika dia miteraka venous na arterial amin'ny sambo lehibe iray (such as a single deep vein thrombosis, pulmonary embolism, or stroke) na fahaverezan'ny fitondrana vohoka miverimberina, ** CAPS dia "rivotra trombotika" mipoaka, mifameno (Thrombotic Microangiopathy [TMA] + Syndrome valin'ny inflammatoire rafitra [SIRS])** izay mibahana miaraka amin'ireo lalan-kely madinika amin'ny rafitra taova telo na mihoatra ao anatin'ny 7 andro latsaka, matetika ny ** voa (73%: fiakaran'ny tosidrà maloto, proteinuria, ary tsy fahampian'ny voa mafy), havokavoka (60%: ARDS, embolisme pulmonary, ary hémorrage alveolar diffuse), ** ati-doha (56%: fahatapahan'ny lalan-dra, fiankinan-doha, thrombose venous cerebral, ary encephalopathie), fo (50%: myocardial micro-infarction sy Libman-Sacks valve vegetations), hoditra (47%: livedo racemosa, ischemia dizitaly maharary, ary necrosis ny hoditra), ary ny fihary adrenal (bilateral adrenal hemorrhage/infarction causing refractory hypotensive shock). Satria ny CAPS dia entin'ny mekanika "Two-Hit", izay misy antibody antiphospholipid (antifosfolipida) efa misy (Lupus Anticoagulant [LA], Anti-Cardiolipin [aCL] IgG/IgM, ary Anti-Beta-2-Glycoprotein-I [aB2GPI] IgG/IgM)** dia nodorana tamin'ny alalan'ny trigger "Second Hit" (bacterial or viral infection in 49%, surgical procedures or trauma in 17%, abrupt withdrawal or subtherapeutic INR of Warfarin, malignancy, pregnancy/puerperium, or oral contraceptive estrogen), ny fanemorana ny fitsaboana dia mitondra 80 to 90 percent taham-pahafatesana, fa ny fanombohana avy hatrany amin'ny ICU ny CAPS "Triple Therapy" dia mampihena ny fahafatesan'ny antsasany. Raha misy marary manana lupus fantatra (SLE), Syndrome antiphospholipid, na thrombocytopenia tsy fantatra dia miteraka soritr'aretina tampoka amin'ny taova maro (shortness of breath, confusion, chest or flank pain, mottled purple skin, or dark/absent urine), antsoy ny eo an-toerana laharana vonjy maika avy hatrany. Avereno jerena ihany koa ny torolalana momba ny mpiara-miasa aminay krizy adrenal sy tsindrona vonjy maika ny aretin'i Addison, eclampsia seizure, HELLP syndrome, ary preeclampsia postpartum, ary sepsis sy septic shock.

Ny sampana vonjy taitra eo noho eo sy ny laharam-pahamehana ao amin'ny ICU dia ny ** manomboka ny "CAPS Triple Therapy" feno miaraka amin'ny ahiahy ara-pitsaboana voalohany momba ny trombose microvascular (WITHOUT waiting days for confirmatory antiphospholipid antibody titers or tissue biopsy)**: (1) Heparine Intravenous Intravenous Intravenous (UFH) (not only to halt fibrin clot propagation, but because heparin directly inhibits complement activation [C3/C5 convertase]), (2) Corticosteroids intravenous dose avo lenta (Methylprednisolone 500 to 1,000 mg/day IV for 3 days, followed by 1 to 2 mg/kg/day) (to extinguish the NF-kappa-B endothelial cytokine storm), ary (3) Fifanakalozana Plasma fitsaboana avy hatrany isan'andro (Plasmapheresis / TPE mifanakalo 1.0 ka hatramin'ny 1.5 ny habetsahan'ny plasma amin'ny Plasma/Albumin Fresh Frozen) SY/OR Immunoglobulin Intravenous Dose avo lenta (IVIG, 0.4 g/kg/day IV for 5 days), eo am-pitsaboana ny tsimok'aretina fototra amin'ny antibiotika midadasika ary mampiasa ny anti-C5 terminal complement inhibitor Eculizumab (Soliris) na anti-CD20 Rituximab ho an'ny tranga refractory.

Ataovy izao izao¶

1. ** Antsoy ny laharan'ny vonjy taitra eo an-toerana na manetsika ICU / Hematology / Rheumatology haingana valiny raha misy marary voan'ny trombose miaraka na tsy fahampian'ny taova maranitra >= 2 to 3 taova ao anatin'ny herinandro.** Antsoy 911 any Etazonia sy Kanada, 999 any Royaume-Uni, 112 manerana ny Vondrona Eoropeana, 000 any Aostralia, na jereo ny lahatahiry momba ny laharana vonjy maika. Tadidio fa 46 to 50 percent amin'ny marary CAPS dia TSY misy fitiliana mialoha ny APS na Lupus (SLE) alohan'ny hidirana ao amin'ny efitrano vonjy maika.
2. Atombohy avy hatrany ny Andry 1 amin'ny CAPS Triple Therapy: Therapeutic Intravenous Unfractionated Heparin (UFH) (Even in the Presence of Moderate Thrombocytopenia or Diffuse Alveolar Hemorrhage)
3. Ny heparine tsy misy fangarony no vato fehizoron'ny CAPS.reducing mortality from > 75% to about 30% ao amin'ny International CAPS Registry) na amin'ny alàlan'ny anticoagulation-mediated antithrombin sy mivantana ** manakana ny lalan-dàlana mahazatra sy hafa **.
4. ** Voahangy Fanaraha-maso laboratoara Critical (The Lupus Anticoagulant aPTT Trap):** Satria ny marary mivezivezy Lupus Anticoagulant (LA) ny antibody dia manitatra ny baseline miankina amin'ny phospholipid aPTT(often to 60 to 100+ seconds * alohan'ny hanombohan'ny* heparine), manara-maso ny heparine tsy voazara IV miaraka amin'ny fenitra aPTT hamitaka anao amin'ny heparine tsy ampy fatrany. Araha-maso foana ny Heparine tsy voazara IV amin'ny CAPS amin'ny fampiasana chromogenic Anti-Factor Xa (Anti-Xa) fitsapana (target 0.3 to 0.7 IU/mL), TSY MISY ny fenitra aPTT.
5. Atombohy avy hatrany ny Andry 2 amin'ny CAPS Triple Therapy: Pulse Intravenous Methylprednisolone (500 to 1,000 mg IV Once Daily for 3 Consecutive Days, Arahin'ny 1 to 2 mg/kg/day IV). Aza manome corticosteroids * irery * tsy misy anticoagulation ao amin'ny CAPS, fa miaraka amin'ny IV Heparin sy Plasmapheresis, ny IV Methylprednisolone avo lenta dia mihidy Anti-Beta-2-Glycoprotein-I (aB2GPI) fampahavitrihana ny endothelial NF-kappa-B ary Tissue Factor ary miaraka amin'izany dia mirakitra fidiran'ny adrenalinina bilateral mahery vaika/infarction (which complicates 13% to 26% of CAPS cases).
6. Atombohy ny Andry 3 amin'ny CAPS Triple Therapy ao anatin'ny ora: Fifanakalozana Plasma Therapeutic Isan'andro (Plasmapheresis / TPE) SY/OR Immunoglobulin intravenous fatra avo (IVIG)
7. ** Fifanakalozana Plasma fitsaboana (TPE, Andalana voalohany indrindra rehefa Schistocytes / Microangiopathic Hemolytic Anemia [MAHA] na misy ny tsy fahombiazan'ny renal):** Fifanakalozana 1.0 to 1.5 plasma volumes isan'andro mandritra ny 3 ka hatramin'ny 5 andro fara-fahakeliny mampiasa Fresh Frozen Plasma (FFP) (na 50:50 FFP + 5% Albumin) mba hanala ny pathogenic aB2GPI ary aCL autoantibodies, cytokines (IL-1, IL-6, TNF-alpha), ary mameno ny sombiny rehefa mameno anticoagulants voajanahary (Antithrombin, Protein C, Protein S, and ADAMTS13).
8. Dose avo IVIG (0.4 g/kg/day IV for 5 days na 1.0 g/kg/day for 2 days): Ampidiro irery (raha tara ny fametrahana catheter apheresis na TPE) na avy hatrany aorian'ny fotoam-pifanakalozana Plasma isan'andro (never infuse IVIG right *before* a TPE session, or the apheresis machine will wash your expensive IVIG straight into the waste bag).
9. ** Mihaza ary karakarao amin'ny fomba mahery setra ny "Second-Hit" precipitating trigger (Infection in 49% of Cases).** Manaova sarin'ny STAT periferika sy tsipika kolontsaina ra, kolontsaina urine, ary takelaka virosy, ary manomboka antibiôtika intravenous empiric broad spectrum avy hatrany raha misy tazo na loharanon'aretina ahiana. Aza atsahatra tampoka ny anticoagulation alohan'ny fandidiana amin'ny marary Triple-Positive APS fantatra (always bridge closely with IV UFH or therapeutic LMWH).
10. ** Ampidiro ny fanakanana ny famenon'ny terminal (IV Eculizumab 900 mg isan-kerinandro) na Rituximab Tany am-piandohan'ny CAPS Refractory na TMA malaza (Schistocytes + Severe Thrombocytopenia + Renal Failure).** Ny porofo ara-panandramana sy klinika dia manaporofo fa ny CAPS henjana dia entin'ny fandosirana Terminal Complement Complex (C5b-9 complex attack membrane) déposition amin'ny sela endothelial (often with underlying complement regulatory gene mutations). Manome IV Eculizumab (Soliris) mampiato ny hemolyse intravascular, thrombocytopenia, ary trombose microvascular renal ao anatin'ny 48 hatramin'ny 72 ora rehefa tsy ampy ny fitsaboana Triple mahazatra.

Hazo fanapaha-kevitra: ahiana ho voan'ny aretina antiphospholipid catastrophic (CAPS / Syndrome Asherson) ary fitsaboana Triple ICU¶

flowchart TD
    Patient["Ny marary dia miseho amin'ny tsy fahombiazan'ny taova maro mivoatra haingana (>= Tava 3 ao anatin'ny <7 andro):<br/>- Renal: Aretina voa mafy, HTN maloto, Proteinuria<br/>- Havokavoka: ARDS / Diffuse Alveolar Hemorrhage / PE<br/>- CNS: Encephaliopathy Cardiac: Troponine avo, Microthrombi myocardial<br/>- Hoditra: Livedo Racemosa, Ganggrène nomerika, Necrosis amin'ny hoditra<br/>- Adrenal: Fanaintainan'ny kibo/kibo + Hypotension refractory"] --> StatWorkup["STAT Bedside & Lab Triage (Aza manemotra ny fitsaboana ho an'ny vokatra antibody):<br/>1. Smear periferika (Schistocytes), LDH, Haptoglobin, Platelets, Coags, Fibrinogen<br/>2. Manaova Lupus Anticoagulant (dRVVT/aPTT), Anti-Cardiolipin IgG/IgM, & Anti-Beta-2-Glycoprotein-I IgG/IgM (TAlohan'ny fifanakalozana Plasma)<br/>3. Ataovy kisendrasendra ny Cortisol & ACTH (Jereo ny fidiran'ny Adrenal Bilateral) + Hetsika ADAMTS13 (Rule Out TTP)"]

    StatWorkup --> TripleTherapy["Atombohy avy hatrany ao amin'ny ICU ny 'CAPS TRIPLE THERAPY' EMPIRIC"]

    TripleTherapy --> Pillar1["Andry 1: Therapeutic IV Unfractionated Heparin (UFH)<br/>- Manara-maso henjana miaraka amin'ny Chromogenic ANTI-FACTOR Xa Level (Target 0.3 hatramin'ny 0.7 IU/mL)<br/>- TSY manara-maso miaraka amin'ny standard aPTT (Falso longure by Lupus Anticoagulant)"]

    TripleTherapy --> Pillar2["Andry 2: Kortikosteroid IV avo lenta<br/>- IV Methylprednisolone 500 hatramin'ny 1,000 mg isan'andro mandritra ny 3 andro, avy eo 1 hatramin'ny 2 mg / kg / andro<br/>- Manakana ny tafio-drivotra endothelial NF-kappa-B & Mitsabo ny krizy adrenal."]

    TripleTherapy --> Pillar3["Andry 3: Fifanakalozana Plasma Therapeutic Isan'andro (TPE) +/- IVIG-Dose avo lenta<br/>- Fifanakalozana 1.0 hatramin'ny 1.5 Vola Plasma Isan'andro x 5+ Andro Mampiasa Plasma Fresh Frozen (FFP)<br/>- Ampidiro IVIG (0.4 g/kg/andro x 5 Andron'ny TPE) TPE IZAY ATAOVY ATAONY"]

    Pillar1 --> TriggerAndRefractory{"Fitsaboana ny 'Second-Hit' Trigger (Antibiotique Broad Spectrum Empiric raha misy otrikaretina) & Tombano ny valiny 24 hatramin'ny 48 ora"}
    Pillar2 --> TriggerAndRefractory
    Pillar3 --> TriggerAndRefractory

    TriggerAndRefractory -->|"Thrombocytopenia refractory, Schistocytes MAHA mitohy, na tsy fahombiazan'ny taova miharatsy"| AddEculizumab["ESCALATE IMMEDIATELY:<br/>1. IV Eculizumab (Anti-C5 Complement Inhibitor: 900 mg IV Weekly x 4, Then 1,200 mg) [Give Meningococcal Vaccine + Ciprofloxacin/Penicillin Prophylaxis]<br/>2. IV Rituximab (375 mg/m2 Weekly x 4) to Deplete B-Cell Autoantibody Production"]

Fizarana 1: Ny Patophysiologie "Two-Hit" amin'ny Syndrome Asherson sy ny fepetra momba ny diagnostika iraisam-pirenena¶

1. Nahoana ny Antibody Antiphospholipid mangina no nipoaka tampoka tao anaty tafio-drivotra 7 andro maromaro¶

Olona maro no mandehandeha mandritra ny taona maro miaraka amin'ny antibody antiphospholipid "Triple-Positive" mivezivezy (Lupus Anticoagulant + Anti-Cardiolipin + Anti-Beta-2-Glycoprotein-I)** tsy misy fidiran'ny rà ("The First Hit"). Nahoana? Satria ao anatin'ny toe-pialan-tsasatra ara-dalàna, ny selan'ny endothelial vaskular dia manafina ny phospholipid membrane misy fiampangana ratsy eo amin'ny takelaka anatiny, ary mivezivezy Beta-2-Glycoprotein-I (B2GPI) mitsinkafona ao anatin'ny endrika boribory mihidy izay manafina ny sehatra mamatotra antigène azy (Domain I).

• Ny "Second Hit" Trigger (Infection, Surgery, Trauma, Pregnancy, or Warfarin Withdrawal):
• Rehefa misy infection (Gram-negative sepsis, respiratory virus, urinary tract infection), trauma amin'ny tavy fandidiana, na fahasimban'ny fahasarotana amin'ny fiterahana na manetsika ny sela endothelial vascular, ny phosphatidylserine misy fiampangana ratsy dia mivadika mankany amin'ny selan'ny sela ivelany.
• Mivezivezy B2GPI binds to the damaged endothelium and uncoils into an open "J-shaped fishhook" conformation, exposing Domain I.
• Pathogenic Anti-Beta-2-Glycoprotein-I (aB2GPI) IgG dimers cross-link the open B2GPI molekiola amin'ny sela endothelial, platelets ary monocytes amin'ny alàlan'ny Toll-Like Receptor 4 (TLR4) and Annexin A2, activating NF-kappa-Bary p38 MAPK.
• ** Ny Loop Fanamafisana Fameno (C3a / C5a / C5b-9):** The bound aB2GPI immune complexes trigger massive activation of the Classical and Alternative Complement Pathways, generating anaphylatoxins C3a ary C5a(which recruit neutrophils to extrude prothrombotic NETs) and punching C5b-9 Membrane Attack Complex pores into microvascular endothelial cells throughout the kidneys, lungs, brain, heart, and adrenal glands.

2. Official Preliminary Classification Criteria for Catastrophic APS (Asherson et al. International Consensus)¶

Clinicians classify a patient as having Definite CAPS (all 4 criteria) or Probable CAPS (3 of 4 criteria) based on: 1. Criterion 1 (>= 3 Organs, Systems, or Tissues): Clinical evidence of involvement of three or more organs, systems, and/or tissues (renal, pulmonary, cerebral, cardiac, cutaneous, hepatic, gastrointestinal/mesenteric, splenic, or adrenal). 2. Criterion 2 (<= 7 Days): Development of clinical manifestations simultaneously or in less than one week. 3. Criterion 3 (Histopathologic Microthrombosis): Confirmation by histopathology of small-vessel occlusion (thrombotic microangiopathy) in at least one organ or tissue (typically via skin punch biopsy of livedo/necrotic lesions or renal biopsy once stabilized). 4. Criterion 4 (Laboratory Antiphospholipid Antibodies): Presence of Lupus Anticoagulant (LA), Anti-Cardiolipin (aCL IgG/IgM at medium-to-high titer > 40 GPL/MPL na > 99th percentile), and/or Anti-Beta-2-Glycoprotein-I (aB2GPI IgG/IgM).

• When to Diagnose "Probable CAPS" and Treat Immediately at the Bedside: Because performing a kidney biopsy in a critically ill, anticoagulated, thrombocytopenic ICU patient is dangerous and waiting 12 weeks for repeat antibody confirmation is impossible during an acute crisis, the International Consensus defines Probable CAPS whenever:
• Only 2 organs are involved (with Criteria 2, 3, and 4 met), OR
• All 4 criteria are met except histopathologic biopsy confirmation is missing (because the patient is too unstable/anticoagulated to biopsy), OR
• 3 organs develop thrombosis over 1 to 4 weeks despite anticoagulation.
• Clinical Rule: Treat Probable CAPS identically to Definite CAPS with immediate full Triple Therapy.

Part 2: Side-by-Side Differential Diagnosis of ICU Thrombotic Microangiopathies (CAPS vs. TTP vs. HUS/aHUS vs. HIT vs. Sepsis DIC)¶

When an ICU patient develops rapidly falling platelets, rising creatinine, neurological confusion, and hemolytic anemia with schistocytes (helmet cells) on the blood smear, distinguishing CAPS from Thrombotic Thrombocytopenic Purpura (TTP), Complement-Mediated Hemolytic Uremic Syndrome (aHUS), HIT, and Septic DIC is critical:

Part 3: Deep-Dive Into the 6 Organ Emergencies of CAPS (Including Bilateral Adrenal Hemorrhage & Diffuse Alveolar Hemorrhage)¶

When managing a CAPS patient in the ICU, clinicians must actively screen for and manage six signature organ crises that determine survival:

========================================================================
   THE 6 SIGNATURE MULTI-ORGAN THROMBOTIC CRISES OF CAPS (ASHERSON'S)
========================================================================

  1. RENAL TMA (73%):               2. PULMONARY CRISIS (60%):
     Renal interlobular/glomerular     ARDS, Pulmonary Embolism, AND
     capillary microthrombi ->         Capillaritis DIFFUSE ALVEOLAR
     Malignant HTN + Oliguric AKI.     HEMORRHAGE (DAH: Hemoptysis +
                                       Falling Hb + Ground-Glass CT).
  3. CEREBRAL / CNS (56%):             * CRITICAL PEARL: Even with DAH,
     Microvascular Encephalopathy,       continue carefully titrated IV
     Seizures, Ischemic Stroke, &        Heparin + Pulse Steroids + TPE.
     Cerebral Venous Sinus Clots.
                                    4. CARDIAC MICRO-INFARCTION (50%):
  5. CUTANEOUS ISCHEMIA (47%):         Intramyocardial microthrombi
     Branching Livedo Racemosa,        (cardiogenic shock with clean
     Splinter Hemorrhages, Digital     epicardial coronaries) + Sterile
     Cyanosis/Gangrene, Skin Ulcers.   Libman-Sacks Mitral/Aortic Valves.

  6. BILATERAL ADRENAL HEMORRHAGE / INFARCTION (13% to 26% - OFTEN MISSED.):
     * Why the Adrenal Glands? Each adrenal gland is fed by 3 arteries
       (50-60 arterioles) but drained by ONLY A SINGLE CENTRAL ADRENAL VEIN.
     * Thrombosis of that single central adrenal vein causes hemorrhagic
       venous infarction of both adrenal cortices -> Sudden Flank/Abdominal
       Pain, Hyponatremia, Hyperkalemia, & Catecholamine-Resistant Shock.
     * Lifesaving Fix: Immediate Stress-Dose IV Hydrocortisone (100 mg IV
       bolus, then 50 mg IV q6h) or Pulse IV Methylprednisolone.
========================================================================

1. The Adrenal Vein Anatomical Bottleneck (Why CAPS Causes Acute Addisonian Adrenal Crisis)¶

Why is bilateral adrenal hemorrhage/infarction a classic complication of both CAPS and HIT? - Every human adrenal gland has a rich arterial supply (superior, middle, and inferior suprarenal arteries branching into 50+ capillary plexus vessels), but all venous blood must exit through a single, solitary Central Adrenal Vein (creating a vascular "water-hammer" bottleneck rich in platelet-activating catecholamines). - When CAPS microthrombi occlude that single central adrenal vein bilaterally, venous pressure inside the adrenal cortex skyrockets until the glands rupture and hemorrhage internally (Waterhouse-Friderichsen-like hemorrhagic infarction). - Clinical Red Flags: If a patient with APS/CAPS develops new bilateral flank, back, or epigastric pain, unexplained fever, falling serum sodium (hyponatremia), rising potassium (hyperkalemia), and hypotension refractory to norepinephrine, order an immediate Abdominal CT (which shows enlarged, hyperdense edematous adrenal glands), draw a STAT random serum Cortisol and ACTH, and immediately administer 100 mg IV Hydrocortisone bolus arahin'ny 50 mg IV every 6 hours (or make sure the patient is already receiving Pulse IV Methylprednisolone).

2. The Pulmonary Paradox: Managing Diffuse Alveolar Hemorrhage (DAH) Inside a Prothrombotic Storm¶

Up to 60 percent of CAPS patients develop acute respiratory failure from ARDS, pulmonary thromboembolism, or non-thrombotic pulmonary capillaritis causing Diffuse Alveolar Hemorrhage (DAH: hemoptysis, diffuse bilateral alveolar infiltrates on chest CT, and a 1.5 to 3.0 g/dL overnight drop in hemoglobin). - How Can a Clotting Disease Cause Lung Bleeding? In CAPS, aB2GPI antibodies and C5a trigger immune-complex pulmonary capillaritis (neutrophilic inflammation that necroses the alveolar capillary wall) combined with pulmonary venular microthrombosis that raises hydrostatic capillary back-pressure until red blood cells pour into the air sacs. - How to Manage DAH in CAPS: 1. Immediately escalate immunosuppression with Pulse IV Methylprednisolone (1,000 mg/day IV x 3 days) + Daily Therapeutic Plasma Exchange (TPE) + IV Cyclophosphamide or Rituximab. 2. Carefully Balance Anticoagulation: If alveolar bleeding is life-threatening and platelets/fibrinogen are critically low, hold IV unfractionated heparin briefly for a few hours while administering Pulse Steroids and Plasma Exchange, but resume low-dose/titrated IV Unfractionated Heparin as soon as active hemoptysis stabilizes, because withholding heparin for days in CAPS allows microvascular thrombosis to destroy the brain, heart, and kidneys.

Part 4: Step-by-Step ICU Triple Therapy Execution & Refractory Rescue (Eculizumab & Rituximab)¶

1. The Exact CAPS Triple Therapy Checklist (McMaster / EULAR / International CAPS Registry Guidelines)¶

2. Famonjena biolojika andalana faharoa ho an'ny CAPS refractory (Eculizumab ary Rituximab)¶

Raha toa ny marary CAPS dia manohy miaina platelets mianjera, mitombo ny creatinine, tsy fahampian'ny neurolojia vaovao, na hemolysis microangiopathic refractory aorian'ny ** 24 hatramin'ny 48 ora Triple Therapy**: 1. Sakantsakana famenon'ny terminal (IV Eculizumab [Soliris] na Ravulizumab [Ultomiris]): - Nahoana no miasa: Efa tapitra 60 percent of patients with refractory CAPS harbor severe complement activation (and many carry heterozygous mutations in complement regulatory genes like CFH, CFI, or CD46 identical to atypical HUS). Eculizumab (a humanized monoclonal antibody against complement protein C5) blocks cleavage of C5 Eo an- C5a ary C5b-9, misambotra ny fandringanana TMA endothelial ao anatin'ny 24 hatramin'ny 72 ora. - Dosing:**900 mg IV indray mandeha isan-kerinandro mandritra ny 4 herinandro, arahin'ny 1,200 mg IV amin'ny herinandro 5 ary isaky ny 2 herinandro aorian'izay. - Mandatory Meningococcal Prophylaxis: Because blocking C5b-9 dia miteraka fahasorenana amin'ny Neisseria meningitidis voafono, mitantana quadrivalent (MenACWYary Serogroup B (MenB) vaksinin'ny meningococcal avy hatrany ARY manomboka fanadiovana antibiotika am-bava isan'andro (Ciprofloxacin 500 mg daily na Penicillin V 500 mg twice daily) manomboka amin'ny Andro 1 amin'ny Eculizumab (do not delay Eculizumab for 2 weeks waiting for vaccine immunity). 2. Mihena ny sela B (IV Rituximab): - Mitantana Rituximab (375 mg/m2 IV indray mandeha isan-kerinandro mandritra ny 4 herinandro, na 1,000 mg IV amin'ny Andro 1 sy 15) (infused after daily TPE) mba hanafoanana CD20+ B-lymphocytes mamokatra autoantibodies antiphospholipid pathogenic, indrindra amin'ny mararin'ny CAPS miaraka amin'ny thrombocytopenia mafy, ny fandosirana alveolar miparitaka, na ny fidiran'ny cardiac / CNS.

Laharana vonjy taitra isam-paritra sy rejistra CAPS iraisam-pirenena¶

• Etazonia sy Kanada: Antsoy ny 911 ho an'izay ahiana ho trombose taova maro na fahatapahan'ny lalan-dra/PE. Araho ny McMaster University Clinical Practice Guideline ho an'ny Diagnose sy Fitantanana ny Syndrome Antiphospholipid Catastrophic (Blood Advances) ary American College of Rheumatology (ACR) / ASH tari-dalana.
• Union Eoropeanina sy Royaume-Uni: Tsindrio ny 112 manerana ny Vondrona Eoropeana na 999 any Angletera. Araho ny ** Alliance European Associations for Rheumatology (EULAR) Tolo-kevitra amin'ny fitantanana ny Syndrome Antiphospholipid amin'ny olon-dehibe (Tektonidou et al., Annals of the Rheumatic Diseases)** ary ny British Society for Hematology (BSH) Torolàlana. Ireo mpitsabo eran-tany dia afaka mijery sy manoratra tranga miaraka amin'ny ** International CAPS Registry (ontocrf.costaisa.com/en/web/caps, hosted by the European Forum on Antiphospholipid Antibodies at Hospital Clínic in Barcelona, Spain, directed by Dr. Ricard Cervera)**.
• Australia and New Zealand: Dial 000 in Australia or 111 in New Zealand. Follow THANZ and Australian Rheumatology Association (ARA) ICU protocols for Triple Therapy and emergency Eculizumab access.

Fanontaniana apetraka matetika¶

Inona no maha samy hafa ny Catastrophic Antiphospholipid Syndrome (CAPS) amin'ny Antiphospholipid Syndrome (APS) mahazatra?¶

In classic Antiphospholipid Syndrome (APS), patients typically experience a single isolated blood clot in a large vein or artery (such as a deep vein thrombosis in one leg, a pulmonary embolism, or a stroke) or recurrent pregnancy complications, with normal function in the rest of their organs. Catastrophic Antiphospholipid Syndrome (CAPS, or Asherson's Syndrome) affects less than 1 percent of APS patients and acts like a sudden, body-wide microvascular "thrombotic storm": instead of one large clot, tiny blood clots simultaneously plug the microscopic capillaries of three or more critical organs (usually the kidneys, lungs, brain, heart, skin, and adrenal glands) within less than 7 days, accompanied by severe systemic inflammation and a falling platelet count.

Why do doctors have to give three treatments at the exact same time ("Triple Therapy") to save a patient with CAPS?¶

Historical data from the International CAPS Registry (covering over 500 patients worldwide) proved that treating CAPS with blood thinners alone or steroids alone failed in the majority of cases, because CAPS has three self-reinforcing engines: (1) Runaway fibrin and complement clotting in small vessels, (2) A fierce inflammatory cytokine storm on the blood vessel walls, and (3) High concentrations of circulating antiphospholipid autoantibodies. "Triple Therapy" attacks all three engines simultaneously: Intravenous Unfractionated Heparin stops clot propagation and inhibits complement, High-Dose IV Methylprednisolone shuts down the endothelial cytokine storm, and Daily Therapeutic Plasma Exchange (Plasmapheresis) and/or IVIG physically removes and neutralizes the autoantibodies, cutting mortality from over 75 percent down to roughly 30 percent.

Why can't nurses and doctors use the standard aPTT blood test to monitor intravenous Heparin in a patient with CAPS?¶

Patients with CAPS almost always have a circulating antiphospholipid antibody called a "Lupus Anticoagulant" (LA). Paradoxically, although a Lupus Anticoagulant causes severe blood clotting inside the human body, inside a glass laboratory test tube it binds to the phospholipid reagents used to run the standard activated Partial Thromboplastin Time (aPTT) test, artificially making the patient's baseline aPTT look prolonged (for example, 85 seconds) before a single drop of heparin is even given. If a clinician uses the aPTT to titrate the heparin drip, they will mistakenly think the patient's blood is "already too thin" and turn the heparin drip down to sub-therapeutic levels while the patient clots to death. Instead, IV Heparin in CAPS must always be monitored with a chromogenic Anti-Factor Xa (Anti-Xa) blood level (targeting 0.3 to 0.7 IU/mL), which is unaffected by the Lupus Anticoagulant.

Why does CAPS frequently cause sudden, life-threatening Adrenal Crisis (Addisonian shock)?¶

Each of your two adrenal glands (which sit on top of the kidneys and produce life-sustaining cortisol and aldosterone) receives blood through dozens of small arteries, but drains all of its blood out through one single Central Adrenal Vein. During a CAPS thrombotic storm, micro-clots easily plug that single draining adrenal vein on both sides. With the exit vein blocked, arterial blood backs up inside both adrenal glands until they swell and rupture internally (bilateral adrenal hemorrhage and infarction). This wipes out the body's cortisol production overnight, causing severe flank or stomach pain, low sodium, high potassium, and fatal low blood pressure unless treated immediately with high-dose intravenous corticosteroids (Methylprednisolone or Hydrocortisone).

Why should patients with Triple-Positive APS or prior CAPS never be switched from Warfarin to a modern Direct Oral Anticoagulant (DOAC) pill like Rivaroxaban or Apixaban?¶

Multiple randomized clinical trials (including the TRAPS and ASTRO-APS trials) were halted early after discovering that patients with "Triple-Positive" Antiphospholipid Syndrome (positive for Lupus Anticoagulant, Anti-Cardiolipin, and Anti-Beta-2-Glycoprotein-I) who took Direct Oral Anticoagulants (DOACs such as rivaroxaban or apixaban) suffered a 4-fold to 7-fold higher rate of arterial strokes and heart attacks than patients taking Warfarin. Blocking only a single clotting factor (Factor Xa or Factor IIa) with a DOAC is often insufficient to stop the massive thrombin and complement surge driven by triple-positive antiphospholipid antibodies, and switching from Warfarin to a DOAC is a documented trigger for acute Catastrophic APS.

Loharano sy tari-dalana ofisialy¶

• McMaster University / ASH Clinical Practice Guideline (Legault K et al., Blood Advances): McMaster RARE-Bestpractices Clinical Practice Guideline for the Diagnosis and Management of the Catastrophic Antiphospholipid Syndrome (Triple Therapy: Anticoagulation, Glucocorticoids, and Plasma Exchange/IVIG).
• European Alliance of Associations for Rheumatology (EULAR, Tektonidou MG et al., Annals of the Rheumatic Diseases): EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults (Contraindication of DOACs in Triple-Positive APS and CAPS Management).
• International Consensus Statement on Classification Criteria and Treatment Guidelines for Catastrophic Antiphospholipid Syndrome (Asherson RA, Cervera R, et al., Lupus / Journal of Rheumatology): Preliminary Classification Criteria for Definite and Probable CAPS and Analysis of 500+ Patients from the International CAPS Registry.
• British Society for Haematology (BSH, Arachchillage DRJ et al.): Guidelines on the Investigation and Management of Antiphospholipid Syndrome and Catastrophic APS.
• New England Journal of Medicine (NEJM) Review (Garcia D, Erkan D): Diagnosis and Management of the Antiphospholipid Syndrome and Complement Inhibition in CAPS.

Mpitarika mifandraika¶

• Adrenal crisis and Addison's disease emergency injection
• Heparin-induced thrombocytopenia (HIT) and VITT: 50 percent platelet drop on Day 5 to 10 and Argatroban
• Eclampsia seizures, HELLP syndrome, postpartum preeclampsia, and magnesium triage
• Sepsis sy septic shock
• Laharana vonjy maika araka ny firenena